semaj83/ctmatch_classification huggingface dataset:
Patient description: Patient A is a 30-year-old male who was admitted to the hospital after 10 days of cough, profuse nocturnal sweating and loss of appetite. He had traveled to India 1 months ago and has not any positive history of TB vaccination. He is a previously healthy man, working as an engineer in a high tech company. He doesn't smoke o use any illicit drugs. He was febrile (38 c) with heart rate of 115 b/min, respiratory rate of 22, BP of 125/75 mmHg and O2 sat of 97%. Chest X-ray showed infiltrate in the middle of left lung with diameter of 1.8 cm with signs of cavitation. The sputum smear revealed positive sputum culture for Mycobacterium tuberculosis which are sensitive of the first-line TB drugs (isoniazid, streptomycin, rifampicin and ethambutol). Lab study is reported bellow: Hgb: 13 g/dl WBC: 14000 /mm3 Plt: 300000 /ml AST: 13 U/L ALT: 15 U/L Alk P: 53 U/L Bill total: 0.6 mg/dl Na: 137 mEq/l K: 4 mEq/l Creatinine: 0.5 mg/dl BUN: 10 mg/dl ESR: 120 mm/hr

Clinical trial eligibility criteria: eligible ages (years): 18.0-65.0,  Asthma Cough Variant Asthma Subjects with asthma or suspected CVA who have previously participated in or who have expressed interest in participating in studies will be invited to participate in the study. Previous treatment with inhaled or systemic corticosteroids is not an criterion, but medication use will be recorded and examined in the analysis  An exacerbation necessitating any alteration in medication, emergency department visit or hospitalizations within the previous 4 weeks; 2. Inability to perform acceptable quality spirometry; 3. Medical contraindications to methacholine challenge testing 35, including: 1. Severe airflow limitation (FEV1 <50% predicted or <1.0 L); 2. Heart attack or stroke in last 3 months; 3. Uncontrolled hypertension, systolic BP > 200 or diastolic BP > 100; 4. Known aortic aneurysm; 5. Moderate airflow limitation < 60% predicted or <1.5 L); 6. Inability to perform acceptable quality spirometry; 7. Current use of cholinesterase inhibitor medication (for myasthenia gravis); and 8. Pregnant or nursing mothers. 4. Smoking history in excess of 10 pack years; 5. Medical contraindications to mannitol challenge testing, including: 1. Aortic or cerebral aneurysm; 2. Uncontrolled hypertension; and 3. Myocardial infarction or a cerebral vascular accident in the previous six months). 6. Women who are pregnant or breastfeeding because the effects of a possible hyperresponsiveness reaction to mannitol in mothers and/or fetuses are unknown and many compounds are excreted in human milk therefore caution should be taken
Patient description: Patient A is a 30-year-old male who was admitted to the hospital after 10 days of cough, profuse nocturnal sweating and loss of appetite. He had traveled to India 1 months ago and has not any positive history of TB vaccination. He is a previously healthy man, working as an engineer in a high tech company. He doesn't smoke o use any illicit drugs. He was febrile (38 c) with heart rate of 115 b/min, respiratory rate of 22, BP of 125/75 mmHg and O2 sat of 97%. Chest X-ray showed infiltrate in the middle of left lung with diameter of 1.8 cm with signs of cavitation. The sputum smear revealed positive sputum culture for Mycobacterium tuberculosis which are sensitive of the first-line TB drugs (isoniazid, streptomycin, rifampicin and ethambutol). Lab study is reported bellow: Hgb: 13 g/dl WBC: 14000 /mm3 Plt: 300000 /ml AST: 13 U/L ALT: 15 U/L Alk P: 53 U/L Bill total: 0.6 mg/dl Na: 137 mEq/l K: 4 mEq/l Creatinine: 0.5 mg/dl BUN: 10 mg/dl ESR: 120 mm/hr

Clinical trial eligibility criteria: eligible ages (years): 18.0-999.0,  Rheumatoid Arthritis Ankylosing Spondylitis Psoriatic Arthritis Patients age greater than or equal to 18 Patients must fulfill international and national guidelines for use of a in RA, PsA and AS (Chest X-ray and purified protein derivative (PPD) skin test negative for tuberculosis). In addition one of the following must be fulfilled unsatisfactory DMARD response defined as failure to treatment with at least two DMARDs including Methotrexate in patients with RA or PsA unsatisfactory NSAID response in patients with AS or unsatisfactory response to prior (in this case patients must have received at least 12 weeks before visit 1) in patients with RA or PsA or AS  Patients who meet contraindications as outlined in the latest version of the Humira syringe® Summary of Product Characteristics (SmPC) and Humira Pen® SmPC Patients participating in another study or clinical trial
Patient description: Patient A is a 30-year-old male who was admitted to the hospital after 10 days of cough, profuse nocturnal sweating and loss of appetite. He had traveled to India 1 months ago and has not any positive history of TB vaccination. He is a previously healthy man, working as an engineer in a high tech company. He doesn't smoke o use any illicit drugs. He was febrile (38 c) with heart rate of 115 b/min, respiratory rate of 22, BP of 125/75 mmHg and O2 sat of 97%. Chest X-ray showed infiltrate in the middle of left lung with diameter of 1.8 cm with signs of cavitation. The sputum smear revealed positive sputum culture for Mycobacterium tuberculosis which are sensitive of the first-line TB drugs (isoniazid, streptomycin, rifampicin and ethambutol). Lab study is reported bellow: Hgb: 13 g/dl WBC: 14000 /mm3 Plt: 300000 /ml AST: 13 U/L ALT: 15 U/L Alk P: 53 U/L Bill total: 0.6 mg/dl Na: 137 mEq/l K: 4 mEq/l Creatinine: 0.5 mg/dl BUN: 10 mg/dl ESR: 120 mm/hr

Clinical trial eligibility criteria: eligible ages (years): 18.0-55.0,  Cystic Fibrosis Adult male or female, between 18 and 55 years of age 2. Documented chronic colonization with Pseudomonas Aeruginosa (Pa) 3. Confirmed diagnosis of CF: 1. Documented history of > 60 mmol/L chloride concentration in pilocarpine sweat chloride test And/Or 2. Genotype with two identifiable mutations consistent with CF, accompanied by one or more phenotypic features consistent with diagnosis of CF 4. Forced expiratory volume in the first second (FEV1) ≥ 30% of predicted value 5. Able to expectorate sputum 6. Serum liver function tests ≤ 2.5 x upper limit of normal 7. Serum urea nitrogen (BUN) and creatinine ≤ 1.5 x upper limit of normal 8. Serum creatinine ≤ 2.0 mg/dl 9. Hemoglobin ≥ 9 g/dl, platelets ≥ 100,000/mm3, and white blood cells (WBC) ≥ 4,500/mm3 and ≤ 15,000/mm3 10. Ionized calcium ≥ the lower limit of normal 11. Able to understand and sign the informed consent document, communicate with the Investigator, and comply with the requirements of the protocol 12. If female and of childbearing potential, must have a negative pregnancy test on Day 1 prior to receiving study drug 13. If female and of childbearing potential, is willing to use adequate contraception, as determined by the investigator, for the duration of the study  Acute pulmonary exacerbation requiring antibiotic intervention within 2 weeks prior to screening 2. Osteoporosis defined as the most recent dexa scan within the prior 5 years with a T-score ≤ -2.5 3. Pregnant or lactating female 4. Known sensitivity to gallium 5. Use of biphosphonates 6. Use of any investigational drug and/or participated in any clinical trial within 3 months prior to screening
Patient description: Patient A is a 30-year-old male who was admitted to the hospital after 10 days of cough, profuse nocturnal sweating and loss of appetite. He had traveled to India 1 months ago and has not any positive history of TB vaccination. He is a previously healthy man, working as an engineer in a high tech company. He doesn't smoke o use any illicit drugs. He was febrile (38 c) with heart rate of 115 b/min, respiratory rate of 22, BP of 125/75 mmHg and O2 sat of 97%. Chest X-ray showed infiltrate in the middle of left lung with diameter of 1.8 cm with signs of cavitation. The sputum smear revealed positive sputum culture for Mycobacterium tuberculosis which are sensitive of the first-line TB drugs (isoniazid, streptomycin, rifampicin and ethambutol). Lab study is reported bellow: Hgb: 13 g/dl WBC: 14000 /mm3 Plt: 300000 /ml AST: 13 U/L ALT: 15 U/L Alk P: 53 U/L Bill total: 0.6 mg/dl Na: 137 mEq/l K: 4 mEq/l Creatinine: 0.5 mg/dl BUN: 10 mg/dl ESR: 120 mm/hr

Clinical trial eligibility criteria: eligible ages (years): 20.0-55.0,  Appetite Suppression Weight Loss BMI 25 Kg/m2  Medications and supplements that affect appetite Known diabetes Contraindications to LCD Any other medical, social or geographic condition, which, in the opinion of the investigator would not allow safe completion of the protocol
Patient description: Patient A is a 30-year-old male who was admitted to the hospital after 10 days of cough, profuse nocturnal sweating and loss of appetite. He had traveled to India 1 months ago and has not any positive history of TB vaccination. He is a previously healthy man, working as an engineer in a high tech company. He doesn't smoke o use any illicit drugs. He was febrile (38 c) with heart rate of 115 b/min, respiratory rate of 22, BP of 125/75 mmHg and O2 sat of 97%. Chest X-ray showed infiltrate in the middle of left lung with diameter of 1.8 cm with signs of cavitation. The sputum smear revealed positive sputum culture for Mycobacterium tuberculosis which are sensitive of the first-line TB drugs (isoniazid, streptomycin, rifampicin and ethambutol). Lab study is reported bellow: Hgb: 13 g/dl WBC: 14000 /mm3 Plt: 300000 /ml AST: 13 U/L ALT: 15 U/L Alk P: 53 U/L Bill total: 0.6 mg/dl Na: 137 mEq/l K: 4 mEq/l Creatinine: 0.5 mg/dl BUN: 10 mg/dl ESR: 120 mm/hr

Clinical trial eligibility criteria: eligible ages (years): 15.0-999.0,  Tuberculosis, Pulmonary Adults (≥16 years on 1st March 2009) Males and Nonpregnant females Active Pulmonary Tuberculosis diagnosed by Sputum Smear positivity for Acid fast bacilli (AFB) Diagnosis within one week of into study Not already on antituberculous treatment Not receiving vitamin D replacement or supplementation  History of having been treated with antimycobacterial therapy for < 6 months or with < 4 first-line anti-tuberculous drugs Extra pulmonary TB Immune suppressed; with HIV infection, hepatic, renal failure, malignancy, diabetes mellitus Sarcoidosis, hyperparathyroidism Already on or requiring corticosteroids, immunosuppressive agents, thiazide diuretics Breast feeding or pregnant Symptomatic cardiac disease Seriously ill or moribund patients with advanced respiratory impairment (cor pulmonale, hypercapnia, respiratory acidosis, congestive cardiac failure) Allergy/sensitivity to study drugs or their formulations
Patient description: Patient A is a 30-year-old male who was admitted to the hospital after 10 days of cough, profuse nocturnal sweating and loss of appetite. He had traveled to India 1 months ago and has not any positive history of TB vaccination. He is a previously healthy man, working as an engineer in a high tech company. He doesn't smoke o use any illicit drugs. He was febrile (38 c) with heart rate of 115 b/min, respiratory rate of 22, BP of 125/75 mmHg and O2 sat of 97%. Chest X-ray showed infiltrate in the middle of left lung with diameter of 1.8 cm with signs of cavitation. The sputum smear revealed positive sputum culture for Mycobacterium tuberculosis which are sensitive of the first-line TB drugs (isoniazid, streptomycin, rifampicin and ethambutol). Lab study is reported bellow: Hgb: 13 g/dl WBC: 14000 /mm3 Plt: 300000 /ml AST: 13 U/L ALT: 15 U/L Alk P: 53 U/L Bill total: 0.6 mg/dl Na: 137 mEq/l K: 4 mEq/l Creatinine: 0.5 mg/dl BUN: 10 mg/dl ESR: 120 mm/hr

Clinical trial eligibility criteria: eligible ages (years): 18.0-999.0,  Multiple Myeloma A histologically established diagnosis of multiple myeloma with evidence of relapse or refractory disease Must have a detectable serum or urine M-Protein by protein electrophoresis that is at least 500 mg/dL (serum) or 1 gm/24 hours (urine), respectively, or serum free light chain level >100 mg/l for the involved free light chain Must have received at least one (1) prior line of systemic treatment that has included either lenalidomide or thalidomide Must be willing to provide correlative blood samples  Must not have received an excessive cumulative dose of anthracycline No ≥ grade 2 peripheral neuropathy No cytotoxic chemotherapy within 30 days prior to registration for protocol therapy No autologous stem cell transplant within 6 months prior to registration for protocol therapy No prior radiation therapy to > 25% of bone marrow forming bones (i.e., pelvis) within 30 days prior to registration for protocol therapy. See Study Procedures Manual to calculate percent of prior radiation No current corticosteroid therapy in doses greater than 10 mg daily of prednisone (or equivalent) if given for management of co-morbid conditions No known central nervous system involvement by myeloma No poorly controlled intercurrent illness including, but not limited to, ongoing or active infection, poorly controlled diabetes, symptomatic congestive heart failure, cardiac arrhythmia, or psychiatric illness/social climate that in the opinion of the investigator would limit compliance with study requirements No patients known to be positive for HIV, or active Hepatitis A, B, or C No major surgery within 30 days prior to registration for protocol therapy. Placement of a venous access device within 30 days prior to registration for protocol therapy is allowed
Patient description: Patient A is a 30-year-old male who was admitted to the hospital after 10 days of cough, profuse nocturnal sweating and loss of appetite. He had traveled to India 1 months ago and has not any positive history of TB vaccination. He is a previously healthy man, working as an engineer in a high tech company. He doesn't smoke o use any illicit drugs. He was febrile (38 c) with heart rate of 115 b/min, respiratory rate of 22, BP of 125/75 mmHg and O2 sat of 97%. Chest X-ray showed infiltrate in the middle of left lung with diameter of 1.8 cm with signs of cavitation. The sputum smear revealed positive sputum culture for Mycobacterium tuberculosis which are sensitive of the first-line TB drugs (isoniazid, streptomycin, rifampicin and ethambutol). Lab study is reported bellow: Hgb: 13 g/dl WBC: 14000 /mm3 Plt: 300000 /ml AST: 13 U/L ALT: 15 U/L Alk P: 53 U/L Bill total: 0.6 mg/dl Na: 137 mEq/l K: 4 mEq/l Creatinine: 0.5 mg/dl BUN: 10 mg/dl ESR: 120 mm/hr

Clinical trial eligibility criteria: eligible ages (years): 0.0-999.0,  Bone Metastases of a Malignant Tumor Patients with an indication for intravenous treatment with an aminobiphosphonate because of a malignant tumor WHO 0,1,2 performance score  WHO 3, 4 performance score prior or current use of aminobisphosphonates -immunosuppressive medication (NSAID allowed) chemotherapy and/or radiotherapy in 4 weeks prior to start of aminobisphosphonate administration renal insufficiency (creatinine clearance < 30 ml/min) liver enzyme abnormalities bilirubin > 1.5 times ULN (upper limit of normal) ASAT or ALAT > 2.5 times ULN (in absence of liver metastases) ASAT or ALAT > 5 times ULN (in presence of liver metastases) concomitant use of strong inhibitors of CYP3A4, such as itraconazole, ketoconazole, erytromycin, clarithromycin, hiv-protease inhibitors or grapefruit juice is contra-indicated
Patient description: Patient A is a 30-year-old male who was admitted to the hospital after 10 days of cough, profuse nocturnal sweating and loss of appetite. He had traveled to India 1 months ago and has not any positive history of TB vaccination. He is a previously healthy man, working as an engineer in a high tech company. He doesn't smoke o use any illicit drugs. He was febrile (38 c) with heart rate of 115 b/min, respiratory rate of 22, BP of 125/75 mmHg and O2 sat of 97%. Chest X-ray showed infiltrate in the middle of left lung with diameter of 1.8 cm with signs of cavitation. The sputum smear revealed positive sputum culture for Mycobacterium tuberculosis which are sensitive of the first-line TB drugs (isoniazid, streptomycin, rifampicin and ethambutol). Lab study is reported bellow: Hgb: 13 g/dl WBC: 14000 /mm3 Plt: 300000 /ml AST: 13 U/L ALT: 15 U/L Alk P: 53 U/L Bill total: 0.6 mg/dl Na: 137 mEq/l K: 4 mEq/l Creatinine: 0.5 mg/dl BUN: 10 mg/dl ESR: 120 mm/hr

Clinical trial eligibility criteria: eligible ages (years): 0.167-4.917,  Community-acquired Pneumonia Children aged between 2 and 59 months Report of respiratory complaints Presence of pulmonary infiltrate on chest x-ray taken on admission and read by the pediatrician on duty  lower chest indrawing danger signs (inability to drink, convulsions, somnolence, central cyanosis, grunting in a calm child) diagnosed underlying chronic diseases (anatomic abnormalities of the respiratory tract, chronic pulmonary illness besides asthma, immunological defects, progressing neurological disorders, psychomotor retardation, heart disease with clinical repercussion, hemoglobinopathy, liver or kidney disease) severe malnutrition other concurrent infection hospitalization during the previous 7 days amoxicillin or similar antibiotic use during the last 48 hours allergy to amoxicillin history of aspiration
Patient description: Patient A is a 30-year-old male who was admitted to the hospital after 10 days of cough, profuse nocturnal sweating and loss of appetite. He had traveled to India 1 months ago and has not any positive history of TB vaccination. He is a previously healthy man, working as an engineer in a high tech company. He doesn't smoke o use any illicit drugs. He was febrile (38 c) with heart rate of 115 b/min, respiratory rate of 22, BP of 125/75 mmHg and O2 sat of 97%. Chest X-ray showed infiltrate in the middle of left lung with diameter of 1.8 cm with signs of cavitation. The sputum smear revealed positive sputum culture for Mycobacterium tuberculosis which are sensitive of the first-line TB drugs (isoniazid, streptomycin, rifampicin and ethambutol). Lab study is reported bellow: Hgb: 13 g/dl WBC: 14000 /mm3 Plt: 300000 /ml AST: 13 U/L ALT: 15 U/L Alk P: 53 U/L Bill total: 0.6 mg/dl Na: 137 mEq/l K: 4 mEq/l Creatinine: 0.5 mg/dl BUN: 10 mg/dl ESR: 120 mm/hr

Clinical trial eligibility criteria: eligible ages (years): 18.0-70.0,  Tuberculosis Subjects who are at least 18 years old and are willing and capable of providing written-informed consent Both men and non-pregnant women will be included One group of 30 patients will have HIV Another group of 30 patients will have drug-resistant TB (MDR or XDR) Remaining 60 patients will have drug-sensitive TB of which 30 will be assigned to placebo TB infection documented prior to Study Entry by either the presence of TB rapid test or sputum smear positive for acid-fast bacilli (AFB) At least two independent tests are sought to confirm TB diagnosis Agreement to participate in the study and to give a sample of blood for HIV testing  Subjects who have already taken V5 in prior trial and those without baseline data Those who met can be retrospectively enrolled Those who are re-treated and relapsed will be eligible as long as they are on the same drug regimen as the rest of patients Pregnant or breast-feeding women are excluded Subjects who have taken anti-retroviral drugs or immunomodulatory therapies within 2 months prior to Entry systemic corticosteroids immune globulin (IV gamma globulin, IVIG) interferons interleukins pentoxifylline (Trental)
Patient description: Patient A is a 30-year-old male who was admitted to the hospital after 10 days of cough, profuse nocturnal sweating and loss of appetite. He had traveled to India 1 months ago and has not any positive history of TB vaccination. He is a previously healthy man, working as an engineer in a high tech company. He doesn't smoke o use any illicit drugs. He was febrile (38 c) with heart rate of 115 b/min, respiratory rate of 22, BP of 125/75 mmHg and O2 sat of 97%. Chest X-ray showed infiltrate in the middle of left lung with diameter of 1.8 cm with signs of cavitation. The sputum smear revealed positive sputum culture for Mycobacterium tuberculosis which are sensitive of the first-line TB drugs (isoniazid, streptomycin, rifampicin and ethambutol). Lab study is reported bellow: Hgb: 13 g/dl WBC: 14000 /mm3 Plt: 300000 /ml AST: 13 U/L ALT: 15 U/L Alk P: 53 U/L Bill total: 0.6 mg/dl Na: 137 mEq/l K: 4 mEq/l Creatinine: 0.5 mg/dl BUN: 10 mg/dl ESR: 120 mm/hr

Clinical trial eligibility criteria: eligible ages (years): 18.0-65.0,  Tuberculosis Adult males or females between 18 and 65 years; women of childbearing potential must be willing to adhere to lifestyle requirements regarding contraception/pregnancy prevention Newly diagnosed sputum smear-positive pulmonary TB confirmed with acid-fast bacillus (AFB) smear and chest x-ray. Patients with TB more than 5 years ago who completed treatment, are healthy, and meet other may be included Body weight between 40 and 90 kg, inclusive (in light clothing, no shoes) Reasonably normal hemoglobin (>=8 gm/dL), renal function (serum creatinine <2 mg/dL), hepatic function (serum AST <3xULN and total bilirubin <1.3 mg/dL), and random glucose <150 mg/dL  HIV infection with helper/inducer T-lymphocytes (CD4 cell) count of <=350x10-6/L Presence of significant hemoptysis. Subjects who cough up frank blood (more than blood streaked sputum) will not be eligible Pregnant or nursing females; females of childbearing potential unwilling or unable to adhere to contraception guidelines Significant respiratory impairment (respiratory rate >35/minute) Clinical suspicion of disseminated TB or tuberculosis meningitis Subjects with diabetes mellitus on insulin and/or who have poorly controlled disease Subjects with confirmed or suspected multi-drug resistant TB